New Immune-Engaging drug takes aim at Hard-to-Treat ovarian cancer
Disease control
Recruiting now
This early-stage trial tests an investigational drug called NTB-928 in women with ovarian cancer that has come back or no longer responds to standard treatments. NTB-928 is designed to direct the body's immune T cells to attack cancer cells by targeting a protein called FRα. The …
Phase: PHASE1 • Sponsor: TeneoSeven, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC